Anticoagulants
are class of drug used for prevention of blood clots. These substances are
majorly available in leeches and blood-sucking insects. These drugs have found
major application in treatment of thrombotic disorders and as supporting drug
during dialysis. The drug is applied on test tubes, transfusion bags, and renal
dialysis equipment for proper functioning. Though the drug class results in
various side effects; anticoagulants play an important role in treatment of
atrial fibrillation, coronary artery disease, deep vein thrombosis, ischemic
stroke, myocardial infraction and pulmonary embolism.
Global anticoagulants
market is broadly divided by type into six segments including Heparin,
Warfarin, Noval Oral Anticoagulants, Vitamin K Antogonists, Direct Thrombosis
Inhibitors, and others. The market is also segmented on the basis of route of
administration into oral and injections. Various global pharmaceutical giants
including Pfizer, Sanofi, GSK, and Baxter provide anticoagulants in their
portfolio for prevention of blood clots.
Aging
population and rising prevalence of coagulation disorders are the major factors
which are expected to drive the anticoagulants market during future. However, unawareness
about the disease especially in emerging and undeveloped economies of Asia,
Latin America and Africa results in large number of undiagnosed cases of
coagulation disorders, hence restraining the market.
Tentative Scope- Global Anticoagulants Market
1.
Executive Summary
2.
Research Methodology
3.
Global Anticoagulants Market
3.1.
By Revenue, 2010-2015
4.
Global Anticoagulants Market Segmentation, 2015
4.1.
By Type
4.1.1. Heparin
4.1.1.1.
Unfractionated
4.1.1.2.
Low Molecular Weight
4.1.1.3.
Ultra Low Molecular Weight
4.1.2. Noval
Oral Anticoagulants (NOACs)
4.1.2.1.
Rivaroxaban
4.1.2.2.
Apixaban
4.1.2.3.
Dabigatran Etexilate
4.1.2.4.
Edoxaban
4.1.3. Vitamin
K Antagonists (VKA)
4.1.4. Injectable
Direct Inhibitors
4.2.
By Route of Administration
4.2.1. Oral
4.2.2. Injectables
4.2.2.1.
Intravenous Route
4.2.2.2.
Subcutaneous Route
4.3.
By Regions
4.3.1. North
America
4.3.2. Europe
4.3.3. Asia
Pacific
4.3.4. Rest
of the World
5.
Snapshot on North America Anticoagulants Market
5.1.
Market by Revenue, 2010 – 2015
5.2.
Market Segmentation
5.2.1. By
Type(Heparin, VKA, NOACs, and Injectable Direct Inhibitors)
5.2.2. By
Countries (US and Canada)
5.3.
Import and Export Scenario
6.
Snapshot on Europe Anticoagulants Market
6.1.
Market by Revenue, 2010 – 2015
6.2.
Market Segmentation
6.2.1. By
Type(Heparin, VKA, NOACs, and Injectable Direct Inhibitors)
6.2.2. By
Countries (France, Germany, Italy, Spain, UK, and Rest of the Europe)*
6.3.
Import and Export Scenario
7.
Snapshot on Asia Pacific Anticoagulants Market
7.1.
Market by Revenue, 2010 – 2015
7.2.
Market Segmentation
7.2.1. By
Type(Heparin, VKA, NOACs, and Injectable Direct Inhibitors)
7.2.2. By
Countries (China, India, Japan, Australia, and Rest of Asia Pacific)*
7.3.
Import and Export Scenario
8.
Snapshot on Patented Anticoagulants Drugs
9.
Trends and Developments in Global Anticoagulants
Market
10.
Regulatory Framework for Global Anticoagulants
Market*
11.
Porter’s Five Forces Analysis for Global Anticoagulants
Market
12.
Market Share of Players in global Global Anticoagulants
Market (Sanofi, Aspen, Pfizer, Leo
Pharma, Novartis and Others)*
13.
Competitive Landscape for Major Players in
Global Anticoagulants Market (Cover Parameters such as company overview, USP, Product
Portfolio, Anticoagulants sales revenues*, margins*, number of employees*,
business strategies, and key personnel)
13.1.Sanofi
13.2.Pfizer
13.3.Leo Pharma
13.4.GlaxoSmithKline
13.5.Bristol Myers Squibb
13.6.Teva Pharmaceutical
Industries
13.7.Baxter Healthcare Corp.
13.8.Others
14.
Anticoagulants Market Future Outlook and
Projections
14.1.By Revenues, 2016- 2020
14.2.By Segments, 2016-2020
14.3.Pipeline Analysis of
Anticoagulants
15.
Analyst Recommendations
16.
Macroeconomic Factors affecting Global Anticoagulants
Market
To know more on the coverage, tap on the link
underneath:
Contact:
